News

New US contracts cool conflict
Enlarge image

BusinessDenmark

New US contracts cool conflict

15.11.2012 - Despite an ongoing dispute, the US government has signed two new contracts with Danish vaccine developer Bavarian Nordic.

The Danish drugmaker announced the closing of two new contracts with the U.S. Department of Homeland Security (DHS) and the National Institutes of Health (NIH). The contracts were valued at up to US$18.9m for the development of recombinant Modified Vaccinia virus Ankara (MVA) vaccines.

The NIH contract, valued at up to US$17.9m, supports the advanced development of an MVA-based human vaccine against the viral haemorrhagic fever Marburg. The DHS contract, valued at nearly US$1m, supports the development of an MVA-based animal vaccine against Foot-and-mouth disease. "These new contracts demonstrate the versatility of our MVA platform for infectious disease vaccines and cancer immunotherapeutics," said Anders Hedegaard, President and CEO of Bavarian Nordic A/S.

Bavarian Nordic is currently in an argument with the US government. Denmark's biggest drugmaker accuses its customer not to fulfil the conditions of a 2007 contract worth US$500m. The government had promised to order 20 million doses of a smallpox vaccine that has less side effects than common ones. As Bloomberg noted, the biotech company had said in August that it would have to shed hundreds of jobs and shut down a plant if the U.S. government didn't order more of the vaccine until January.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-04/new-us-contracts-cool-conflict.html

2014EU

19.12.2014 We took a look back at 2014: which European Biotechnology News stories topped the charts this year?

R&DEUBelgium

18.12.2014 IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

Events

All Events

Current issue

All issues

Product of the week

Products